Pegasys market share
Executive Summary
Roche Pegasys share of new prescriptions is 26% in the U.S. for the first quarter, up from 23% at the end of 2002, company tells analyst call April 10. The hepatitis C therapy may get a boost from the 15,000 patients who received peginterferon alfa-2a for three months free of charge ahead of the Copegus combination approval (1"The Pink Sheet" Oct. 21, 2002, p. 10)...